-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on July 11, Ruikang Pharmaceutical's intraday daily limit, the stock has achieved 4 consecutive daily limit since July As of the close on the 11th, Ruikang Pharmaceutical's quotation was 70 yuan, the turnover was 535 million, the turnover rate was 27%, and the price-earnings (TTM) was 99Regarding the recent abnormal fluctuations in the company's stock trading, it is reported that the relevant person in the investor relations department of Ruikang Pharmaceutical responded: It should be possible to obtain Evusheld (Enshide) as an agent in mainland Chi.
Evusheld is a passive anti-COVID-19 antibody developed by AstraZeneca, and currently there is no similar competitor in the wor.
According to the announcement of AstraZeneca, the research and development company of the drug, the drug is suitable for adults and adolescents (age ≥ 12 years old and weight ≥ 40kg) for pre-exposure prophylaxis against the new coronavirus, and it is difficult for people who are difficult to produce sufficient antibody protection against the new crown vaccine, including those who do not People who are recommended to be vaccinat.
In China, Evusheld has not yet been listed, but according to relevant policies, Evusheld can be used in Hainan Boao Lecheng Medical Tourism Pilot Zone, and appointments can be made in Ruijin Hainan Hospital and Boao Super Hospit.
Ruikang Pharma stated in the abnormal stock trading announcement released on July 8 that after verification with the company's investor relations department and all staff of the board office, the relevant personnel have not issued the above-mentioned response to the media, and the company has not passed the Shenzhen Stock Exchange Interactive Trading, Websites and other channels claim the content of the above-mentioned media repor.
The announcement mentioned that the company has long-term cooperation with AstraZeneca, and there is a strategic partnership and business relationsh.
The company reached a "Strategic Cooperation Memorandum" with AstraZeneca on October 19, 202As of the date of this announcement, the company has not signed any agreement with AstraZeneca regarding the agency of Evusheld in mainland Chi.
According to the data, Ruikang Pharma is a pharmaceutical distribution company that sells medicines, medical equipment, and medical consumables directly to medical institutions across the count.
The 2021 annual report shows that Ruikang Pharmaceutical achieved operating income of 2060 billion yuan for the year, a year-on-year decrease of 267%; net profit attributable to the parent was 131 million yuan, a year-on-year decrease of 48
In addition, according to the company's 2022 first quarter report, in the first quarter of this year, the company achieved operating income of 093 billion yuan, a year-on-year decrease of 299%; net profit attributable to the parent was 47366 million yuan, a year-on-year decrease of 46
It is worth mentioning that Ruikang Pharmaceutical has received inquiries about annual reports for many years, and related subsidiaries are often mention.
According to its annual report, from 2016 to 2019, the company's consolidated subsidiaries expanded rapidly, from more than 90 to more than 30During the period, the company's performance also experienced rapid growth, but in 2019, Ruikang Pharmaceutical achieved a net profit of -928 million yuan attributable to the parent, a sharp drop of 223% compared with the same period in 201As for the reason for the loss, Ruikang Pharmaceutical attributed that most of the company's subsidiaries achieved profits, but the performance did not meet expectatio.
Due to the many uncertainties faced by future operations, based on the principle of prudence, the company made provision for 82 asset grou.
The impairment provision for reputation is 837 billion yu.
If this impact is excluded, the company will realize a net profit of 27 billion yu.
As of December 31, 2021, Ruikang Pharma had a total of 253 subsidiaries included in the scope of consolidation, and 34 subsidiaries were newly included in the scope of consolidation during the year; 12 subsidiaries were disposed of and 20 were cancelled during the ye.
There are 14 subsidiaries not included in the scope of consolidati.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
Evusheld is a passive anti-COVID-19 antibody developed by AstraZeneca, and currently there is no similar competitor in the wor.
According to the announcement of AstraZeneca, the research and development company of the drug, the drug is suitable for adults and adolescents (age ≥ 12 years old and weight ≥ 40kg) for pre-exposure prophylaxis against the new coronavirus, and it is difficult for people who are difficult to produce sufficient antibody protection against the new crown vaccine, including those who do not People who are recommended to be vaccinat.
In China, Evusheld has not yet been listed, but according to relevant policies, Evusheld can be used in Hainan Boao Lecheng Medical Tourism Pilot Zone, and appointments can be made in Ruijin Hainan Hospital and Boao Super Hospit.
Ruikang Pharma stated in the abnormal stock trading announcement released on July 8 that after verification with the company's investor relations department and all staff of the board office, the relevant personnel have not issued the above-mentioned response to the media, and the company has not passed the Shenzhen Stock Exchange Interactive Trading, Websites and other channels claim the content of the above-mentioned media repor.
The announcement mentioned that the company has long-term cooperation with AstraZeneca, and there is a strategic partnership and business relationsh.
The company reached a "Strategic Cooperation Memorandum" with AstraZeneca on October 19, 202As of the date of this announcement, the company has not signed any agreement with AstraZeneca regarding the agency of Evusheld in mainland Chi.
According to the data, Ruikang Pharma is a pharmaceutical distribution company that sells medicines, medical equipment, and medical consumables directly to medical institutions across the count.
The 2021 annual report shows that Ruikang Pharmaceutical achieved operating income of 2060 billion yuan for the year, a year-on-year decrease of 267%; net profit attributable to the parent was 131 million yuan, a year-on-year decrease of 48
In addition, according to the company's 2022 first quarter report, in the first quarter of this year, the company achieved operating income of 093 billion yuan, a year-on-year decrease of 299%; net profit attributable to the parent was 47366 million yuan, a year-on-year decrease of 46
It is worth mentioning that Ruikang Pharmaceutical has received inquiries about annual reports for many years, and related subsidiaries are often mention.
According to its annual report, from 2016 to 2019, the company's consolidated subsidiaries expanded rapidly, from more than 90 to more than 30During the period, the company's performance also experienced rapid growth, but in 2019, Ruikang Pharmaceutical achieved a net profit of -928 million yuan attributable to the parent, a sharp drop of 223% compared with the same period in 201As for the reason for the loss, Ruikang Pharmaceutical attributed that most of the company's subsidiaries achieved profits, but the performance did not meet expectatio.
Due to the many uncertainties faced by future operations, based on the principle of prudence, the company made provision for 82 asset grou.
The impairment provision for reputation is 837 billion yu.
If this impact is excluded, the company will realize a net profit of 27 billion yu.
As of December 31, 2021, Ruikang Pharma had a total of 253 subsidiaries included in the scope of consolidation, and 34 subsidiaries were newly included in the scope of consolidation during the year; 12 subsidiaries were disposed of and 20 were cancelled during the ye.
There are 14 subsidiaries not included in the scope of consolidati.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
